Liver transplantation offers live-saving therapy for patients with complications of cirrhosis
and stage T2 hepatocellular carcinoma. The demand for organs far outstrips the supply, and …

Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic
steatohepatitis (NASH), represents the fastest growing indication for liver transplantation in …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

非アルコール性脂肪性肝疾患 (NAFLD) は, 慢性肝疾患の主な原因である. 多くはプライマリケアや
病院における肝酵素の上昇や脂肪肝の画像所見により, 偶発的に診断される. NAFLD …

There is increasingly growing evidence and awareness that prehabilitation in waitlisted solid
organ transplant candidates may benefit clinical transplant outcomes and improve the …

Das Fortschreiten einer NASH ist assoziiert mit Leberzellstress, konsekutiver Entzündung
und Fibrose, mit potentieller Entwicklung einer Leberzirrhose, portaler Hypertension und der …

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver
transplantation (LT) in Western Countries, both for end stage liver disease and …

In March 2019, the American Gastroenterology Association (AGA) published a clinical
practice update on the surgical risk in individuals with cirrhosis. 1 Improved management …

Currently, there are no approved medications to treat patients with nonalcoholic
steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these …

Non‐alcoholic steatohepatitis (NASH) is the most common cause of liver disease in Western
populations, and its prevalence is increasing rapidly. It is part of a multisystem disease …